These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11706406)

  • 41. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
    Seymour L; Ivy SP; Sargent D; Spriggs D; Baker L; Rubinstein L; Ratain MJ; Le Blanc M; Stewart D; Crowley J; Groshen S; Humphrey JS; West P; Berry D
    Clin Cancer Res; 2010 Mar; 16(6):1764-9. PubMed ID: 20215557
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How large should a phase II trial of a new drug be?
    Simon R
    Cancer Treat Rep; 1987 Nov; 71(11):1079-85. PubMed ID: 3315196
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.
    Ivy SP; Siu LL; Garrett-Mayer E; Rubinstein L
    Clin Cancer Res; 2010 Mar; 16(6):1726-36. PubMed ID: 20215542
    [TBL] [Abstract][Full Text] [Related]  

  • 44. European Commission considers revisions to clinical trials directive.
    Mason E
    J Natl Cancer Inst; 2010 Mar; 102(5):292-4, 297. PubMed ID: 20173121
    [No Abstract]   [Full Text] [Related]  

  • 45. Envisioning the future of early anticancer drug development.
    Yap TA; Sandhu SK; Workman P; de Bono JS
    Nat Rev Cancer; 2010 Jul; 10(7):514-23. PubMed ID: 20535131
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
    Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Eisenhauer EA; Seymour LK
    Eur J Cancer; 2008 Jan; 44(1):25-9. PubMed ID: 17845846
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rational combinations using HDAC inhibitors.
    Bots M; Johnstone RW
    Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular biological design of novel antineoplastic therapies.
    Vulfovich M; Saba N
    Expert Opin Investig Drugs; 2004 Jun; 13(6):577-607. PubMed ID: 15174947
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical trial design for target-based therapy.
    Fox E; Curt GA; Balis FM
    Oncologist; 2002; 7(5):401-9. PubMed ID: 12401902
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor.
    Gimsing P
    Expert Opin Investig Drugs; 2009 Apr; 18(4):501-8. PubMed ID: 19335278
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overview of the clinical efficacy of investigational anticancer drugs.
    Nygren P; Larsson R
    J Intern Med; 2003 Jan; 253(1):46-75. PubMed ID: 12588538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SOP 13: Pharmacokinetic data analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():56-9. PubMed ID: 23570190
    [No Abstract]   [Full Text] [Related]  

  • 54. Adaptive design may hasten clinical trials.
    Schmidt C
    J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
    [No Abstract]   [Full Text] [Related]  

  • 55. Update on new drugs in small cell lung cancer.
    Horn L; Castellanos EL; Johnson DH
    Expert Opin Investig Drugs; 2011 Apr; 20(4):441-5. PubMed ID: 21395484
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New nucleoside analogues in clinical development.
    Faderl S; Gandhi V; Kantarjian H; Plunkett W
    Cancer Chemother Biol Response Modif; 2002; 20():37-58. PubMed ID: 12703199
    [No Abstract]   [Full Text] [Related]  

  • 57. Compressing drug development timelines in oncology using phase '0' trials.
    Kummar S; Kinders R; Rubinstein L; Parchment RE; Murgo AJ; Collins J; Pickeral O; Low J; Steinberg SM; Gutierrez M; Yang S; Helman L; Wiltrout R; Tomaszewski JE; Doroshow JH
    Nat Rev Cancer; 2007 Feb; 7(2):131-9. PubMed ID: 17251919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.
    Lee SM; Backenroth D; Cheung YK; Hershman DL; Vulih D; Anderson B; Ivy P; Minasian L
    J Clin Oncol; 2016 Apr; 34(12):1395-401. PubMed ID: 26926682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of angiogenesis in cancer patients.
    Verheul HM; Pinedo HM
    Expert Opin Emerg Drugs; 2005 May; 10(2):403-12. PubMed ID: 15934875
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.